Loading organizations...
§ Private Profile · London, United Kingdom
MultiplAI Health is a technology company.
MultiplAI Health develops universal blood screening tests, leveraging RNA Sequencing and Artificial Intelligence to detect complex diseases. The company's core offering focuses on early identification for conditions like cardiovascular disorders and cancers, utilizing advanced genomic analysis. This approach provides proactive and comprehensive health assessment, enabling earlier intervention in disease progression.
The company was co-founded by Charlie Luzzani, Mark Ramondt, and Santiago Miriuka. Their collective insight focused on addressing the critical need for more effective and accessible early detection methods for chronic diseases. They recognized the transformative potential of combining genomic sequencing with advanced AI, shifting healthcare towards a proactive, preventive model for patient care.
MultiplAI Health's product is intended for individuals and healthcare providers seeking comprehensive health monitoring and early disease management. The company envisions a future where universal, remote genomic screening is a standard practice in preventive medicine. Its long-term mission is to enhance global health outcomes by enabling widespread, proactive identification and intervention for complex diseases.
MultiplAI Health has raised $3.0M across 1 funding round.
MultiplAI Health has raised $3.0M in total across 1 funding round.
MultiplAI Health has raised $3.0M in total across 1 funding round.
MultiplAI Health's investors include Francisco Buchara, Crispin Payne, Cristian Hernandez-Cuevas, 2150, Breakthrough Energy Ventures, VoLo Earth Ventures.
MultiplAI Health is a biotechnology company specializing in universal genomic screening for complex diseases, primarily cardiovascular disorders and cancer, using advanced RNA-based and AI-driven technologies. Their flagship product is a whole blood test that detects molecular variances indicating increased risk of cardiovascular events, enabling early and accurate screening accessible to a broad population. This innovation addresses the global burden of cardiovascular diseases, the leading cause of death worldwide, by facilitating routine, remote, and precise screening to improve prognosis and treatment outcomes[1][2][3].
Founded in September 2020, MultiplAI Health was established by a team of experts in molecular biology, cardiology, biotech innovation, data science, and healthcare entrepreneurship. The idea emerged from the need to transform cardiovascular disease diagnosis through a comprehensive RNA sequencing approach combined with artificial intelligence, moving beyond single biomarker detection to a "superbiomarker" that captures complex molecular changes. Early traction includes strategic partnerships and a business combination agreement with APx Acquisition Corp. I and OmnigenicsAI to create a global AI-driven genomics platform, signaling strong market interest and growth potential[1][2][4].
MultiplAI Health rides the convergence of precision medicine, AI, and genomics, capitalizing on advances in RNA sequencing, bioinformatics, and machine learning to address the massive global health challenge of cardiovascular diseases. The timing is critical as healthcare increasingly shifts toward preventive, personalized, and remote diagnostics, driven by rising chronic disease burdens and the need for scalable screening tools. By enabling early detection through a non-invasive blood test, MultiplAI Health influences the broader ecosystem by pushing forward the integration of AI and genomics in routine clinical practice, potentially reducing healthcare costs and improving patient outcomes worldwide[2][3].
Looking ahead, MultiplAI Health is poised to expand its impact by broadening its screening capabilities beyond cardiovascular diseases to other complex conditions like cancer. The company’s growth will likely be shaped by continued advances in AI, sequencing technologies, and healthcare digitization trends. As it scales globally through partnerships and public market access, MultiplAI Health could become a key player in transforming preventive health management, making routine genomic screening a standard of care and significantly influencing the future of personalized medicine[1][2][3].
This trajectory ties back to their mission of making universal, precise, and accessible screening a reality, addressing one of the most pressing health challenges of our time.
MultiplAI Health has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in March 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2023 | $3M Seed | Francisco Buchara, Crispin Payne, Cristian Hernandez Cuevas | 2150, Breakthrough Energy Ventures, VoLo Earth Ventures | Announced |